{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000034","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.877673+00:00","generated_at":"2026-05-16T03:10:34.643129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B","bullets":["FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.","GAAP net income $4.0B in FY2025 vs net loss of $(536)M in 2024; cash $12.3B.","FY2026 revenue guidance $12.95–$13.1B; non-CF product revenue expected ≥$500M.","JOURNAVX: >550,000 prescriptions filled in 2025; coverage for >200M U.S. lives.","Rolling BLA for povetacicept in IgAN on track for completion in H1 2026; ALYFTREK pediatric study completed."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000034","json":"https://secwatch.observer/filing/0000875320-26-000034.json","markdown":"https://secwatch.observer/filing/0000875320-26-000034.md","text":"https://secwatch.observer/filing/0000875320-26-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/0000875320-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/vrtx-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:10:34.643129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}